Live from the congress
EADO 2019 Congress brings you real-time coverage of some sessions of the scientific programme.
Click on the following links to access the sessions’ highlights:
Scientific highlights : Day 1 - April 24
Scientific highlights : Day 2 - April 25
Scientific highlights : Day 3 - April 26
Scientific highlights : Day 4 - April 27
EADO 2019 speakers share the highlights of their session in video.
Martine BAGOT | New monoclonal antibodies for the treatment of CTCL
There is an antibody directed against anti-KIR3DL2 that is the killer in inhibitory receptor specifically expressed by advanced CTCL cells.
Christian BLANK | Neoadjuvant immunotherapy in melanoma
They will discuss neoadjuvant therapy, neoadjuvant immunotherapy and targeted therapy. This is now the second round for the most successful therapies : immunotherapy and targeted therapy, where we now bring this to earlier stage.
Matilda BYLAITE-BUCINSKIENE | Looking forward to meeting you in Vilnius
Prof. Dr. Matilda Bylaitė-Bučinskienė invites you to attend the 16th EADO Congress in Vilnius (Lithuania) next year, the only international congress with such scientific sharing on melanoma and non-melanoma skin cancers.
Brigitte DRENO | EADO 2019 Congress Speaker
Brigitte DRENO presents the huge progress in non-melanoma skin cancer. There is now immunotherapy with two molecules for the Merkel cell carcinoma with significant response. Also, immunotherapy is arriving for squamous cell carcinoma.
Claus GARBE | Skin cancer becomes more and more important because the incidence rates rise. One of the EADO's main tasks is to improve prevention.
Alexandra GEUSAU & Christophe HOELLER | What is Scope?
Jean-Jacques GROB | What is a difficult to treat BCC?
Should we indicate treatment for stage II melanoma because we are already giving BRAF inhibitors and immunotherapy in stage III-A (equivalent to stage II in terms of prognosis)?
Céleste LEBBE | Combining as opposed to sequencing: we gain advantage for patient in combining targeted therapy BRAF and MEK inhibitors.
Josep MALVEHY | Dermoscopy and confocal microscopy cases 1
For Josep Malvehy, ex-vivo confocal microscopy will change the scenario in Europe and many other countries through better surgical assessment of skin cancer margins, especially in patients with skin cancers that are difficult to eliminate or when the limits are undetermined.
Grant MCARTHUR | Molecular resistance to targeted therapy, from bench to bedside
The biggest challenge we have to face today is the resistance to targeted therapy in vast majority of patients with BRAF muted melanoma.
Paul NGHIEM | Biology and therapy of Merkel cell carcinoma
Therapies are now both less toxic and more effective for patients. For instance, with radiations, you do not need to do big surgery.
Alexander STRATIGOS | EADO Vice - President
The EADO congress is a gathering of experts from different fields (dermatology, epidemiology, research) with a specific interest for dermato-oncology and with the mission of promoting clinical care, education and collaborative research.
Mariano SUPPA | New technologies for the diagnosis of skin cancer in the spotlight.
Friday, April 26th, Mariano SUPPA will present several technologies for non-invasive skin imaging, from high-definition ultrasound to confocal microscopy.
Eric VIVIER | EADO 2019 Congress Speaker
To improve immuno-oncology and help T-cells to fight against cancer, we can use innate immune cells by using antibodies.
David WHITEMAN | Which percentage of melanoma is caused by UV radiation, and what proportion could be prevented?
As the epidemiology of melanoma decreases in the New World (Australia, New Zealand and USA), it continues to grow in the Old World in a worrying way (Central Europe, UK, Scandinavia).